Publication: J Surg Oncol. 2022;125:596–602.

Authors: Jennifer A. Crozier MD | Julie Barone DO | Pat Whitworth MD |Abraham Cheong MD | Robert Maganini MD | Jose Perez Tamayo MD | Patricia Dauer PhD | Shiyu Wang MS | William Audeh MD | Annuska M. Glas PhD

Title: High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer

Abstract

Methods: Matched tumor specimens (n = 121) were prospectively collected from women enrolled in the FLEX trial (NCT03053193). Concordance is reported using overall percentage agreement and Cohen’s kappa coefficient. Correlation is reported using Pearson correlation coefficient.

Background and Objectives: With increased neoadjuvant therapy recommendations for early‐stage breast cancer patients due to the COVID‐19 pandemic, it is imperative that molecular diagnostic assays provide reliable results from preoperative core needle biopsies (CNB). The study objective was to determine the concordance of MammaPrint and BluePrint results between matched CNB and surgical resection (SR) specimens.

Results: We found good concordance for MammaPrint results between matched tumor samples (90.9%, κ = 0.817), and a very strong correlation of MammaPrint indices (r = 0.94). The concordance of BluePrint subtyping in matched samples was also excellent (98.3%).

Conclusions: CNB samples demonstrated high concordance with paired SR samples for MammaPrint risk classification and BluePrint molecular subtyping, suggesting that physicians are provided with accurate prognostic information that can be used to guide therapy decisions.